L'intérêt à découvert pour ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests (BATS:ARKB), Rapport sur les intérêts à découvert

In seeking to achieve its investment objective, the Trust will hold bitcoin. The Trust is sponsored by 21Shares US LLC (the Sponsor), a wholly-owned subsidiary of Amun Holdings Ltd. The Sponsor has entered into a marketing and sub-advisory agreement (the Support Services Agreement) with ARK Investment Management LLC (the Sub-Adviser) to serve as the Trusts sub-adviser and provide assistance in the marketing of the Shares.

ARK 21Shares Bitcoin ETF

ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests

Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing, each pursuant to the contingent value rights agreement (the "CVR Agreement").
The Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Elevation Oncology stockholders and has approved the Merger Agreement and related transactions.

News

ELEV

Concentra Biosciences To Acquire Elevation Oncology For $0.36 In Cash Per Share Of Elevation Oncology Common Stock, Plus One Non-Tradeable Contingent Value Right

Telsey Advisory Group analyst Joseph Feldman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and maintains $115 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Walmart, Maintains $115 Price Target

<ul>
<li>New Drug Submission filed by Lipocine's licensing partner Verity Pharma</li>
<li>Over 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large commercial opportunity</li>
</ul>
SALT LAKE CITY, June 9, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that its licensing partner, Verity Pharma, filed a New Drug Submission (NDS) for TLANDO&#xAE; in Canada.&nbsp; TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.

LPCN

Lipocine Says Licensing Partner, Verity Pharma, Files New Drug Submission For TLANDO In Canada

Analysts' ratings for Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.75, along with a high estimate of $52.00 and a low estimate of $12.00. Experiencing a 0.68% decline, the current average is now lower than the previous average price target of $37.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749470464_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Regenxbio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regenxbio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Regenxbio's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Regenxbio's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RGNX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regenxbio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Regenxbio: A Closer Look</h2>
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
<h3>Financial Insights: Regenxbio</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Regenxbio showcased positive performance, achieving a revenue growth rate of 469.79% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Regenxbio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regenxbio's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Regenxbio's ROA excels beyond industry benchmarks, reaching 1.27%. This signifies efficient management of assets and strong financial health.
Debt Management: Regenxbio's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.29.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGNX

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) saw a sharp decline last week as the <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">tensions</a> between Elon Musk and President Donald Trump flared up on social media, however, this expert predicts no change in its long-term view despite the fall.
What Happened: After Trump and Musk&#8217;s public spat on Thursday, the automaker erased over <a href="https://www.benzinga.com/markets/market-summary/25/06/45809203/investors-pay-the-price-as-musk-trump-war-of-words-escalates-once-allies-now-foes-their-li">$152 billion in market capitalization</a>; however, Tom Lee, the CIO at Fundstrat Capital, remains positive on the stock.
In a video reshared on X, Lee said, the decline that we have seen recently is just coming back to support.
&#8220;I don&#8217;t think the long-term picture has changed much for Tesla,&#8221; he said.
Furthermore, he highlighted Tesla&#8217;s leadership and competitive strength in electric vehicle design and manufacturing, an affordable robotaxi product launching soon, Optimus robots with movement dexterity, and its foray into drones.
&#8220;Will all that Tesla still holds all of its advantages, so we aren&#8217;t too concerned about the decline,&#8221; Lee added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> is a <a href="https://twitter.com/hashtag/grannyshot?src=hash&amp;ref_src=twsrc%5Etfw">#grannyshot</a> &#x1f447;<a href="https://twitter.com/hashtag/SaturdayVibes?src=hash&amp;ref_src=twsrc%5Etfw">#SaturdayVibes</a> <a href="https://twitter.com/search?q=%24GRNY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GRNY</a> <a href="https://t.co/eqL0Ccjiog">https://t.co/eqL0Ccjiog</a>
&mdash; Thomas (Tom) Lee (not drummer) FSInsight.com (@fundstrat) <a href="https://twitter.com/fundstrat/status/1931428856038060361?ref_src=twsrc%5Etfw">June 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Wedbush analyst Dan Ives <a href="https://www.benzinga.com/markets/tech/25/06/45830730/dan-ives-remains-bullish-on-tsla-stock-despite-trump-elon-musk-feud-expects-regulatory-framework-for">also reiterated Lee&#8217;s views</a>, saying that &#8220;Trump/Musk going from BFFs to frenemies does not change our bullish view of the autonomous path looking forward.&#8221;
He said that Wedbush still expects Trump to green light the regulatory federal framework for autonomous vehicles regardless of the feud.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump/Musk going from BFFs to frenemies does not change our bullish view of the autonomous path looking forward. Trump we still expect to have green light regulatory federal framework for autonomous looking forward regardless of this feud. Musk driving Tesla's AI future &#x1f525;&#x1f3c6;&#x1f37f;&#x1f402;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1931774968985264232?ref_src=twsrc%5Etfw">June 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/25/06/45828107/larry-summers-identifies-3-key-reasons-for-rising-us-debt-but-doesnt-think-trumps-big-beautiful-bill">Larry Summers Identifies 3 Key Reasons For Rising US Debt, But Doesn&#8217;t Think Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Is The Medicine The Country Needs</a>
Why It Matters: Tensions rose between Musk and Trump when he called the &#8220;Big Beautiful Bill&#8221; a "<a href="https://www.benzinga.com/news/politics/25/06/45757029/elon-musk-slams-congressional-spending-bill-as-a-disgusting-abomination" target="_blank" rel="noreferrer noopener">disgusting abomination</a>" earlier this week, and both were seen allaying accusations against each other over the disagreement on the bill Thursday.
However, the stock rose 3.67% on Friday after a signal that both parties could be&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/45807968/trump-signals-truce-with-elon-musk-after-online-feud-its-going-very-well-never-done-better" target="_blank" rel="noreferrer noopener">headed for a truce</a>.
Lee&#8217;s Fundstrat Granny Shots US Large Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNY#NYSE">GRNY</a>), which <a href="https://grannyshots.com/holdings/">holds about</a> 38 stocks, includes Tesla with 2.27% of weight.
Apart from this, the exchange-traded fund&#8217;s top holdings include Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a weight of 3.06%, General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) at 2.96%, GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) at 2.83% and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) weighting 2.79%.
The GRNY ETF has gained 7.28% on a year-to-date basis, and it has been up 4.30% since its inception in November last year. Despite Tesla&#8217;s decline, the ETF rose 3.04% over the last week.
Shares of Tesla slumped 14.11% in the last week, and they were down by 22.18% in 2025. However, over the last year, the stock has risen by 69.83%.
Benzinga Edge Stock Rankings show that TSLA had a weaker price trend over the short and medium term, but a strong price trend over the long term. Its momentum ranking was solid, whereas its value ranking was weak at the 9.28th percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="153" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09014421/TSLA-EDGE-FRESH-1024x153.png" alt="" class="wp-image-942642" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09014421/TSLA-EDGE-FRESH-1024x153.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09014421/TSLA-EDGE-FRESH-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09014421/TSLA-EDGE-FRESH-768x115.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09014421/TSLA-EDGE-FRESH.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Friday. The SPY was up 1.03% to $599.14, while the QQQ advanced 0.98% to $529.92, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of the S&amp;P 500, Dow Jones, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45816468/ai-data-centers-are-eating-electricity-and-these-3-energy-stocks-could-be-the-biggest-winners-says-analyst">AI Data Centers Are Eating Electricity — And These 3 Energy Stocks Could Be The Biggest Winners, Says Analyst </a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

Tech

GRNY

HOOD

NVDA

TSLA

Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: 'Tesla Still Holds All Of Its Advantages, So We Aren't Too Concerned'

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $83.67, a high estimate of $90.00, and a low estimate of $72.00. A 2.25% drop is evident in the current average compared to the previous average price target of $85.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1749470452_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Axos Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>David Feaster</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Andrew Liesch</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axos Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axos Financial compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axos Financial's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Axos Financial's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axos Financial analyst ratings.</a>
<h2>Unveiling the Story Behind Axos Financial</h2>
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
<h3>Understanding the Numbers: Axos Financial's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3M period, Axos Financial showcased positive performance, achieving a revenue growth rate of 4.94% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Axos Financial's net margin is impressive, surpassing industry averages. With a net margin of 34.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Axos Financial's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Axos Financial's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Axos Financial's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Axos Financial: 6 Analysts Share Their Views

Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) ("Canaan" or the "Company"), an innovator in crypto mining, today announced that its chairman and chief executive officer, Nangeng Zhang, and its chief financial officer, James Jin Cheng, had purchased additional shares of the Company's stock in the open market. Such transactions complied with the Company's internal trading policy as well as relevant laws and regulations.
Mr. Zhang and Mr. Cheng together acquired an aggregate of 817,268 American Depositary Shares ("ADSs") at an average price of US$0.76 per ADS. These purchases demonstrate their continued confidence in the Company's long-term prospects.

Canaan Announces CEO & CFO Stock Purchases: 817,268 ADSs Acquired At $0.76 Each

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) with a Buy and lowers the price target from $30 to $12.

ANVS

HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $12

More than half of U.S. adults could not pay a $2,000 <a href="https://www.benzinga.com/money/what-is-an-emergency-fund">emergency bill</a> from savings, the Federal Reserve's latest survey data shows, shining a light on the fragility of family finances despite a strong labor market.
What Happened: According to the survey of Household Economics and Decision-Making, only 48% said they would cover the expense with cash on hand. The rest would borrow, cut spending, or simply default.
Inflation tops the list of worries for the third straight year. 37% of respondents called rising prices their main financial challenge, up from 35% last year and four times the 2016 level. Separate Bankrate polling finds just 44% of households have enough savings to handle a $1,000 shock, a share that&#8217;s barely changed since 2022.
Savings gaps stretch wide. 18% of adults keep less than $100 set aside, 13% hold between $100 and $499, and another 10% sit in the $500-to-$999 range. Fed researchers say those figures mirror the 62% who still live paycheck to paycheck, a proportion LendingClub confirms in data from late 2023.
See also: <a href="https://www.benzinga.com/markets/tech/25/06/45833310/jeff-bezos-on-his-heroes-why-he-sees-edison-as-a-symbol-of-invention-and-disney-as-a-master-of-vision">Jeff Bezos On His Heroes: Why He Sees Edison As A Symbol Of Invention And Disney As A Master Of Vision</a>
Why It Matters: Economists warn that the thin cushions leave households vulnerable to even modest setbacks. Personal-finance nonprofit NEFE notes growing support for mandatory high-school money courses after studies link class-takers to higher emergency funds and lower late fees. Twenty-three states now require the instruction, up from 17 before the pandemic.
Policymakers see mixed signals. The Fed report shows 55% of adults have <a href="https://www.benzinga.com/personal-finance/24/07/39613246/is-your-emergency-fund-ahead-of-the-curve-the-savings-needed-to-be-in-the-top-5-for-your-age-gro">rainy-day savings</a> equal to three months of expenses, yet that share trails the 59% peak hit in 2021. With prices still climbing at 3% annually, CFPB data show late-payment rates on credit cards and auto loans are at their highest in years.
New York Times best-selling author Ramit Sethi, who also hosts Netflix&#8217;s new show &#8220;How to Get Rich,&#8221; <a href="https://www.benzinga.com/personal-finance/25/04/45014802/ramit-sethi-shares-the-first-step-you-can-take-to-improve-your-finances-thats-when-you-take-control-of-your-money">urges families</a> to automate transfers into high-yield accounts and aim for at least one month of expenses before tackling larger goals.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/news/politics/25/06/45833339/ken-griffin-slams-trump-for-chasing-tax-cuts-and-low-wage-manufacturing-questions-push-toward-lowest-paid-workforce-in-the-world">Ken Griffin Slams Trump For Chasing Tax Cuts And Low-Wage Manufacturing, Questions Push Toward &#8216;Lowest Paid Workforce In The World&#8217;</a>

Financial Advisors

Personal Finance

Most Americans Can't Cover A $2,000 Emergency As Inflation Keeps Eating Their Paychecks, Survey Shows

Telsey Advisory Group analyst Cristina Fernandez maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Outperform and lowers the price target from $280 to $255.

Telsey Advisory Group Maintains Outperform on RH, Lowers Price Target to $255

CSW Industrials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSW#NYSE">CSW</a>) (the "Company") today announced the commencement of trading of the Company's common stock on the New York Stock Exchange ("NYSE") under the new ticker symbol, "CSW". Trading on the NYSE will begin at market open today, June 9, 2025.

CSW Industrials Begins Trading On NYSE Under New Ticker Symbol 'CSW' On June 9

Telsey Advisory Group analyst Dana Telsey maintains Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) with a Market Perform and maintains $2 price target.

BRLT

Telsey Advisory Group Maintains Market Perform on Brilliant Earth Group, Maintains $2 Price Target

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

XCF Global, Inc. ("XCF") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel ("SAF"), announced that its Class A common stock will begin trading at market open today on the Nasdaq Capital Market under the ticker symbol "SAFX." The announcement follows the closing of XCF's business combination with Focus Impact BH3 Acquisition Company on June 6, 2025.

SAFX

XCF Global Announces Class A Common Stock To Begin Trading On Nasdaq Capital Market On June 9 Under Ticker Symbol "SAFX"

Senator Elizabeth Warren (D-Mass.) is calling for an independent investigation into the Department of Government Efficiency&#8217;s alleged access to sensitive student loan data, raising questions about privacy and security of federal education systems managing trillions in student debt.
What Happened: Warren requested the Department of Education&#8217;s Office of Inspector General to review DOGE&#8217;s access to the agency&#8217;s internal federal student loan database, <a href="https://abcnews.go.com/Politics/warren-urges-department-education-ig-investigate-doge-access/story?id=122556299">reported</a> ABC News. &#8220;The full extent of DOGE&#8217;s role and influence at ED remains unknown,&#8221; Warren wrote in a letter obtained by ABC News. The Federal Student Aid systems handle a $1.6 trillion student loan portfolio for over 40 million borrowers.
Ten Democratic senators joined Warren&#8217;s request, saying the Education Department refused to disclose information about DOGE&#8217;s database access scope. The department cited &#8220;ongoing litigations&#8221; when declining to answer questions about data security measures and employee access protocols.
Education Secretary Linda McMahon testified that DOGE employees received standard agency access levels during their audit to identify waste and fraud. Warren&#8217;s separate investigation raised concerns about a DOGE employee whose database access was revoked, with questions remaining about other system privileges.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45833310/jeff-bezos-on-his-heroes-why-he-sees-edison-as-a-symbol-of-invention-and-disney-as-a-master-of-vision">Jeff Bezos On His Heroes: Why He Sees Edison As A Symbol Of Invention And Disney As A Master Of Vision</a>
Why It Matters: Warren&#8217;s concerns reflect broader scrutiny of DOGE operations. House Democrats previously alleged the agency is building <a href="https://www.benzinga.com/25/04/44888379/elon-musks-doge-under-fire-house-democrats-say-agency-is-building-unlawful-master-database-of-sensitive-us-data">an unlawful cross-agency master database</a>, with whistleblowers reporting DOGE engineers consolidating sensitive federal data systems. 
Warren is also part of a group of Senate democrats behind the <a href="https://www.benzinga.com/news/politics/25/06/45810097/protecting-seniors-data-act-to-audit-doges-access-of-social-security-systems-identify-backdoor-channels-report">Protecting Seniors&#8217; Data Act of 2025</a>, which would instruct the Government Accountability Office to conduct audits of all SSA systems accessed by DOGE staff. 
Federal courts recently <a href="https://www.benzinga.com/general/education/25/05/45638372/trump-blocked-from-shifting-student-loan-oversight-from-education-department-to-small-business-administration-federal-court-ruling">blocked Trump administration attempts </a>to transfer student loan oversight from Education to Small Business Administration, maintaining current departmental structure. Despite DOGE&#8217;s <a href="https://www.benzinga.com/25/04/44759007/did-elon-musk-just-lower-doges-1-trillion-savings-target-to-150-billion-in-a-second-revision-since-jan">claimed $150 billion savings</a> target, <a href="https://www.benzinga.com/markets/25/03/44297088/despite-elon-musks-efforts-us-spending-soars-to-new-highs-deficit-exceeds-1-trillion">federal spending increased </a>$154 billion since Trump&#8217;s return to office.
Warren&#8217;s &#8220;Save Our Schools&#8221; campaign opposes administration efforts to dismantle the Education Department, citing potential consequences for borrowers as the agency faces staff reductions and operational changes.
Image via Shutterstock
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45833037/auto-industry-struggles-as-supply-chain-issues-threaten-production-amid-chinas-export-curbs-on-rare-earth-minerals-report">Auto Industry Struggles As Supply Chain Issues Threaten Production Amid China&#8217;s Export Curbs On Rare Earth Minerals: Report</a></li>
</ul>

Education

Elizabeth Warren Demands Probe Into Alleged Student Loan Data Breach Amid Push To Dismantle Education Department

Birks Group Inc. (the "Company", "Birks Group" or "we") (NYSE American LLC: BGI) is pleased to provide an update on its corporate activities.
All figures presented herein are in Canadian dollars.
The Company has entered into a commitment letter with SLR Credit Solutions ("SLR"), one of the Company's current senior lenders, whereby SLR has committed to provide the Company with an additional term loan of $13.5million subject to the satisfaction of certain conditions precedent (the "Incremental Loan"). The Incremental Loan would bear interest at the same rate as our current term loan with SLR which is CORRA plus (i) a CORRA adjustment of 0.32% and (ii) 7.75%, and it would be repayable, in full, on December 24, 2026. The proceeds of the Incremental Loan are to be used by the Company to fund a strategic acquisition of jewellery stores (the "Acquisition") and to fund ordinary course working capital. In connection with the Acquisition, the Company has entered into a share purchase agreement to acquire jewellery stores located in a Canadian province where the Company already operates. The Acquisition is subject to a number of conditions precedent, including certain third-party consents and satisfaction of other conditions and covenants customary for an acquisition of this nature. Contemporaneously with the Incremental Loan, Mangrove Holding S.A., one of the Company's controlling shareholders, will enter into a loan agreement with the Company to advance $3.75 million of additional indebtedness to fund our working capital requirements, at an annual interest rate of 15%, which would be repayable, in full, on December 24, 2026, subject to the satisfaction of certain conditions precedent.
The Company gives no assurance that it will be able to satisfy these conditions and consummate the proposed Acquisition, Incremental Loan and the Mangrove Holding financing on these or any terms.
The Company continues to be actively engaged in identifying alternative transactions to continue pursuing its strategic goals including raising additional funds through public or private equity, debt financing, and the completion of strategic acquisitions or divestitures.

Birks Group Secures C$13.5M Incremental Loan From SLR Credit Solutions

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong.
The highly anticipated presentation will be delivered by Francisco Silva, Vice President of Research and Development at BioRestorative, on Friday, June 13, at 5:00 p.m. HKT, as part of ISSCR 2025's clinical innovations track. The Company will issue a press release pre-market that day, detailing the newly reported data.
"This represents a milestone moment for BioRestorative," said Lance Alstodt, Chief Executive Officer. "With preliminary data from twice as many patients as previously shared, we are seeing strong, consistent signals around both safety and functional improvement. We are eager to bring this update to the global scientific community at the world's most influential stem cell conference."
BRTX-100 is BioRestorative's lead clinical candidate — a hypoxic-cultured, autologous mesenchymal stem cell therapy designed to target areas of the body with limited blood flow, such as damaged spinal discs. The ongoing Phase 2 study is a prospective, randomized, double-blinded, placebo-controlled trial evaluating BRTX-100 in patients with cLDD across up to 16 U.S. clinical sites. A total of 99 patients will be enrolled, randomized 2:1 to receive either BRTX-100 or placebo via a single intradiscal injection.
The presentation, titled "Stem Cell Therapy for Chronic Lumbar Disc Disease: Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells," will highlight key preliminary outcomes focused on patient-reported pain and function metrics, as well as safety endpoints.

BRTX

BioRestorative to Present Stem Cell Trial Data for Back Pain at Global Conference

<a href="https://www.globenewswire.com/Tracker?data=xW7y0U7yaxM-NAOnpvBJN5ONNQG6webZJnF0umC10PnWkzR0hDM0eG1CjQgGs-hGAiSavGjQDy-RhT6zZ_nIARc8RBoUJorBwZ6yhFR4tKI=">LeddarTech&#xAE; Holdings Inc.</a> ("LeddarTech" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, <a href="https://www.globenewswire.com/Tracker?data=xW7y0U7yaxM-NAOnpvBJNxF3qX8qT-L3MpiXuKWkkaZpZqnVkOEis0OVyfuLiMxZvOzw1Zp5OF_IsoIWXHs_3ccNRL721ZV0ONnQQTMBgPyeP_tYddL123d7oAh7HMuM">LeddarVision</a>&#x2122;, today announced that it has entered into:
&nbsp;
<ul>
<li>a sixth amending agreement (the "Sixth Amending Agreement") with the initial bridge lenders, certain members of management and the board of directors and FS Investment Management (collectively, the "Bridge Lenders") with respect to the bridge financing offer dated as of August 16, 2024 (the "Bridge Financing Offer") pursuant to which the Bridge Lenders have agreed to, among other things, extend the maturity of the bridge loan to January 31, 2026.</li>
</ul>
The Sixth Amending Agreement to the Bridge Financing Offer also provides for a new bridge to equity term loan by FS Investment Management in the amount of up to US$2,000,000 for the purposes of providing LeddarTech with the cash necessary to complete one or more equity investments or commercial transactions involving LeddarTech and its technology.

LDTC

LeddarTech And Bridge Lenders Finalize Sixth Amendment, Bridge Loan Maturity Extended To 2026

Lipocine Shareholders Approved Amendment to Cut Authorized Common Stock From 200M to 75M Shares at Annual Meeting Held on June 4, 2025

<a href="https://www.globenewswire.com/Tracker?data=xW7y0U7yaxM-NAOnpvBJN5ONNQG6webZJnF0umC10PnWkzR0hDM0eG1CjQgGs-hGAiSavGjQDy-RhT6zZ_nIARc8RBoUJorBwZ6yhFR4tKI=">LeddarTech&#xAE; Holdings Inc.</a> ("LeddarTech" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, <a href="https://www.globenewswire.com/Tracker?data=xW7y0U7yaxM-NAOnpvBJNxF3qX8qT-L3MpiXuKWkkaZpZqnVkOEis0OVyfuLiMxZvOzw1Zp5OF_IsoIWXHs_3ccNRL721ZV0ONnQQTMBgPyeP_tYddL123d7oAh7HMuM">LeddarVision</a>&#x2122;, today announced that it has entered into:
<ul>
<li>an eighteenth amending agreement (the "Eighteenth Amending Agreement") with Fédération des caisses Desjardins du Québec ("Desjardins") with respect to the amended and restated financing offer dated as of April 5, 2023 (the "Desjardins Credit Facility"), pursuant to which Desjardins has agreed to, among other things, temporarily postpone certain payments of interest and fees until January 31, 2026, subject to acceptable cash flow projected payments.</li>
</ul>

LeddarTech And Desjardins Agree To Eighteenth Amendment, Payments Postponed Until 2026

ARK 21Shares Bitcoin ETF Beneficial Interest

Comments

ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests

Intérêt court

ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests (BATS:ARKB), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL